Aileron Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALRN Nasdaq 8731 http://www.aileronrx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Aileron Therapeutics Inc

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer - May 19th, 2022 11:00 am
3 Oversold Biotech Stocks to Buy Now - May 19th, 2022 10:40 am
Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference - May 17th, 2022 11:00 am
Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022 - May 13th, 2022 11:00 am
Will Aileron Therapeutics (NASDAQ:ALRN) Spend Its Cash Wisely? - May 11th, 2022 11:57 am
Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting - May 10th, 2022 4:43 pm
Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights - May 5th, 2022 8:15 pm
Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year? - Apr 21st, 2022 1:40 pm
Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations - Apr 21st, 2022 12:00 pm
Is Aileron Therapeutics, Inc. (ALRN) Stock Outpacing Its Medical Peers This Year? - Apr 5th, 2022 1:40 pm
Aileron Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Highlights - Mar 28th, 2022 8:20 pm
Aileron Therapeutics to Participate in Maxim Group 2022 Virtual Growth Conference - Mar 22nd, 2022 12:04 pm
Morgan Jess S & Co Inc Buys Wells Fargo, PowerShares QQQ Trust Ser 1, NVIDIA Corp, Sells ... - Jan 27th, 2022 6:38 pm
Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones - Jan 5th, 2022 1:04 pm
Aileron Therapeutics to Present at Upcoming Investor Conferences - Jan 4th, 2022 1:45 pm
CEO Presenting on the Emerging Growth Conference on January 5 Register Now - Jan 4th, 2022 12:00 pm
As Aileron Therapeutics, Inc.'s market cap (NASDAQ:ALRN) drops to US$47m, insiders might be questioning their decision to buy earlier this year - Dec 30th, 2021 9:32 am
Aileron Therapeutics Issues Statement on Passing of Scientific Advisory Board Member and Nobel Laureate Robert H. Grubbs - Dec 20th, 2021 3:56 pm
Aileron Therapeutics Reports Third Quarter 2021 Financial Results and Business Highlights - Nov 12th, 2021 12:50 pm
Aileron Therapeutics Presents Data at AACR-NCI-EORTC International Conference Demonstrating ALRN-6924’s Activity as Radioprotective Agent in Preclinical Models of Acute Radiation-Induced Toxicity - Oct 7th, 2021 1:22 pm